RESEARCH AND DEVELOPMENT DAY
Verastem Research and Development Day 2014 Agenda • – Robert Forrester ‐Verastem President and Chief Executive Officer • From the Front Line: Mesothelioma Care and the Patient Experience – Mary ... Get Content Here
FAK INHIBITOR VS-6063 - Home | ECMC
Mesothelioma 11 Verastem, Inc. Confidential November 12, 2014 FAK EC 50 = 15 nM PYK2 EC 50 = 95 nM . Page VS-6063 (Defactinib) Highlights •Good safety profile across several clinical trials •Early signs of clinical activity ... Read Document
FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma ...
Verastem, Inc. | 117 Kendrick St. | Suite 500 | Needham | Massachusetts | 02494 FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma . Cancer Stem Cells Which Are Enriched by Standard of Care Chemotherapy . Jonathan A. Pachter. 1, Vihren N. Kolev. 1 ... View Document
FEATURES - Science
Verastem Inc., Weinberg’s company in Needham, Massachusetts, is one of several cancer and in mesothelioma patients who responded to traditional chemo to prevent the cancer from recurring. Reparixin, a drug initially developed by ... Fetch Document
STRAYING FROM THE PATH - Broad Street Alerts
Verastem Inc. – One Catalyst mesothelioma, ovarian, non-small cell lung and other cancers, such as breast cancer. Recent News and Analysis According to analysts, Verastem, Inc. is expected to report earnings per share for the current fiscal quarter of $-0.45. ... Visit Document
Translational Research - Oxford Journals
Translational research 1601P VS-6063 (DEFACTINIB) mesothelioma. Defactinib is a potent, orallyactive FAK kinase inhibitor thathas Verastem, Inc. Stock Ownership in Verastem, Inc.; J.A. Pachter: Employee of Verastem, ... Return Document
Novel Mechanisms Of Sensitivity And Acquired Resistance To ...
Sara Busacca, PhD Abstract: 2739 MO12 Verastem 2) Received research funding from Synta Pharmaceuticals and Pierre-Fabre . Hsp90 as a molecular target in mesothelioma ... Doc Viewer
Orphan Drug Designations And Approvals List As Of 09 03 2013
Orphan Drug Designations and Approvals List as of 09 amino)benzamide hydrochloriden/a 7/18/2013 Treatment of mesothelioma Verastem, Inc. 188 amatuximab n/a 9/28/2012 Treatment of mesothelioma Morphotek, Inc. ... Retrieve Here
FAK VS 4718 Preferentially Of P1.14 With NF2 Mutation: Role Of
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the pleural lining of the lung often caused by asbestos exposure. Microsoft PowerPoint - Verastem Poster Presentation iMig poster 2012.pptx Author: bsullivan Created Date: ... Read Document
Oncology Drugs In The Pipeline
Defactinib (VS-6063, Verastem) mesothelioma, non–small cell lung cancer (KRAS-mutant disease) phase 2 demcizumab (OncoMed Pharmaceuticals) ovarian cancer phase 2 mesothelioma who have received at least one line of prior chemotherapy ... View This Document
The mesothelioma Applied Research Foundation Presents The ...
The mesothelioma applied research foundation (CHAIR: RICHARD ALEXANDER, MD) Marc De Perrot, MD, University of Toronto Mitchell Keegan, PhD, Verastem IMMUNOTHERAPIES (CHAIR: RAFFIT HASSAN, MD) Aimee Murphy, Aduro Bio Tech, Inc. ... Doc Viewer
Text To70070 Investigates mesothelioma Newsletter
In mesothelioma research and the new project recently funded by JHMRF. Professor Adrian Dobbs, from the University the drug company Verastem. Called the COMMAND study, the research will look at whether people with malignant ... Fetch This Document
Tumor Suppressor Alterations Cooperate To Drive Aggressive ...
Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Malignant mesothelioma is a highly aggressive, J.A. Pachter is VP/Head of Research in Verastem. No potential conflicts of ... Access This Document
Tumor Suppressor Alterations Cooperate To Drive Aggressive ...
Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with 4Verastem Inc., Cambridge MA 02142 5These authors contributed equally to this work. Running Title: A clinically relevant mouse model of mesothelioma Keywords: malignant mesothelioma, ... Read Document
No Slide Title
•Verastem . Epidemiology of Mesothelioma • Incidence: – 2,500-3,000 cases year in the US – 5,000 cases per year in Western Europe – An emerging problem in the developing world • Onset 20 to 60 years following asbestos exposure ... Get Content Here
Verastem To Present Preclinical Data At The 2015 EORTC-NCI-AACR International Conference On Molecular Targets And ...
Verastem, Inc. today announced four poster presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 5-9, 2015 in Boston, Massachusetts. ... Read News
Alimta Fda Approval
The only FDA-approved drug for the treatment of mesothelioma. Verastem Chief Medical Officer Dr. At the time of the first-line approval, the FDA also approved a change to the second-line indication. ALIMTA is now indicated as a single agent for the treatment. ... Get Doc
Update On mesothelioma - CancerCare
Able to manage mesothelioma and experience a better quality of life. update on mesothelioma 800-813-hope (4673) info@cancercare.org This fact sheet has been made possible by Verastem, Inc. affect cancer cells in those areas. The standard chemotherapy option for mesothelioma is Pemetrexed ... Fetch Here
Edison Research Template
Verastem is a research client of Edison Investment Research Limited Verastem will shortly begin a series of studies that should provide definitive proof-of- Verastem to focus on mesothelioma as VS-6063’s first indication. ... Access Full Source
Novel Therapeutics In Mesothelioma - YouTube
Mary Hesdorffer, MS, NP, of the Meso Foundation and Lee Krug, MD, of the Memorial Sloan-Kettering Cancer Center moderate a panel at the 2014 International Symposium on Malignant Mesothelioma on novel therapeutics and clinical trials. Presenters include Dirk Brockstedt, PhD, of Aduro ... View Video
Verastem Mesothelioma Trial Disclosed
12 June 2013 Verastem is a research client of Edison Investment Research Limited Verastem’s investor update at ASCO 2013 disclosed the detailed design of ... Return Document
No comments:
Post a Comment